Nuzenio

Vidya Therapeutics

Vidya Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 22 latest news signals 19 publisher sources 100/100 entity strength

Latest news

Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - mintz.commintz.com · Tue, 04 Aug 2026 12:00:00 GMTThe Pharma Letter M&A round-up – July 2026 - The Pharma LetterThe Pharma Letter · Mon, 03 Aug 2026 13:49:16 GMTAlnylam’s slump deepens; Q2 earnings roundup; and more - Endpoints NewsEndpoints News · Sat, 01 Aug 2026 10:00:00 GMTFunding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 31 Jul 2026 13:42:10 GMTInizio Engage launches Connected Insights | PharmExec - Pharmaceutical ExecutivePharmaceutical Executive · Thu, 30 Jul 2026 17:57:09 GMTProcessa acquires CNS-penetrant BTK inhibitor VT-7208 with USD 200m financing for three Phase II programs - AllSciAllSci · Thu, 30 Jul 2026 16:13:05 GMTProcessa acquires Vidya and its BTK inhibitor - The Pharma LetterThe Pharma Letter · Thu, 30 Jul 2026 12:02:43 GMTM&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK - Pharmaceutical ExecutivePharmaceutical Executive · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Tue, 04 Aug 2026 12:00:00 GMTMintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - mintz.com
Mon, 03 Aug 2026 13:49:16 GMTThe Pharma Letter M&A round-up – July 2026 - The Pharma Letter
Sat, 01 Aug 2026 10:00:00 GMTAlnylam’s slump deepens; Q2 earnings roundup; and more - Endpoints News
Fri, 31 Jul 2026 13:42:10 GMTFunding Roundup: Braveheart, Attovia, Vogenx All Announce IPO’s - Pharmaceutical Executive
Thu, 30 Jul 2026 17:57:09 GMTInizio Engage launches Connected Insights | PharmExec - Pharmaceutical Executive
Thu, 30 Jul 2026 16:13:05 GMTProcessa acquires CNS-penetrant BTK inhibitor VT-7208 with USD 200m financing for three Phase II programs - AllSci

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Vidya Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

19 distinct publisher/source names are currently connected to this entity page.